A
Alcista
Alcista · 25%TAK
$18.07
Precio del escenario
$20.240
-0.119 (-0.59%)Al cierre
Loading chart…
- Máximo
- 20.390
- Apertura
- 20.280
- Precio medio ponderado por volumen
- 20.27
- Volumen
- 2.10M
- Capitalización
- 40.51B
- Mínimo
- 20.170
- Importe
- 42.54M
- EV/EBITDA, TTM
- 3.05
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
Análisis de IA of Takeda Pharmaceutical Co Ltd (TAK)
ComprarTakeda Pharmaceutical Co Ltd is a good buy right now due to its current price of 20.24, a strong year-to-date change of +29.58%, and an RSI of 75.75 indicating bullish momentum. The upcoming earnings date on October 29, 2026, with an EPS estimate of 0.31, adds to the potential for positive price movement. However, the main risk is the recent net income fluctuations, with a significant loss of -368.47 billion JPY reported in Q4 2026.
Métricas de valoración
El PER previsto actual de Takeda Pharmaceutical Co Ltd (TAK) es 11.47, frente a su media de 5 años de 25.19.
Escenarios de precio de Alphio AI para TAK
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.010-23NewsfilterArcotatug Tavatecan Shows Promising Results in Advanced Gastric Cancer Study
- 2.010-19Newsfilter
ENTYVIO Treatment Shows Significant Efficacy in UC Patients
- 5.010-15Newsfilter
ORZEYFUL Approved for Launch in Japan and China
- 9.009-30Newsfilter
Zasocitinib Shows Superiority in Psoriasis Treatment
- 9.009-22Newsfilter
Takeda Unveils New Data at ESMO Congress on Cancer Treatments
Preguntas frecuentes sobre TAK, respondidas por Alphio AI
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies. It operates in the Healthcare sector.
Takeda Pharmaceutical Co Ltd is a good buy right now due to its current price of 20.24, a strong year-to-date change of +29.58%, and an RSI of 75.75 indicating bullish momentum. The upcoming earnings date on October 29, 2026, with an EPS estimate of 0.31, adds to the potential for positive price movement. However, the main risk is the recent net income fluctuations, with a significant loss of -368.47 billion JPY reported in Q4 2026.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.